People's Republic of China (PRC)'s Kangxinuo Biological Co., Ltd. is one of the leading enterprises of biological vaccine in China, with a production system comparable to international quality standards and a research and development system with a global vision. Kangxinuo Biological Co., Ltd. was established in Tianjin, China on June 5438+10/October 65438+March, 2009, and is committed to the research and development of public health in China and the world. Production and commercialization of innovative vaccines. The company has four innovative vaccine platform technologies, including adenovirus vector vaccine technology. Combinatorial technology. Protein design and recombination technology. Preparation technology.

In 2020, the company has established a 16 vaccine research and development pipeline, covering 13 infectious diseases, including the recombinant Ebola virus vaccine approved on 20 17 and the recombinant novel coronavirus vaccine under research.